Roche has reported early-stage clinical ... which is a consideration with some drugs in the oral GLP-1 class. For example, Novo Nordisk's oral formulation of semaglutide for diabetes – Rybelsus ...

Five scientists won this year’s Breakthrough Prize in Life Sciences for their work on GLP-1 and the development of drugs for ...

The race is under way to make faster, cheaper and better GLP-1 drugs that will go beyond reducing obesity levels to treating ...

The Centers for Medicare and Medicaid Services (CMS) announced Friday it will not be finalizing a rule proposed by the Biden ...

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for GLP-1 weight-loss drugs. Current runners-up Viking Therapeutics ( VKTX 2.08 ...

Swiss drugmaker Roche on Wednesday announced a major deal in the weight-loss category, agreeing to pay up to $5.3 billion to Zealand Pharma in a licensing and development deal.

Related Massive study looks at benefits, risks of GLP-1 weight-loss drugs GLP-1 medications show promise in slowing kidney disease progression Cosmetic surgeons try to correct 'Ozempic face' for ...

The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...

Roche is expanding its scope to a promising ... developing amylin drugs aim to spark weight loss comparable to GLP-1 drugs while offering better tolerability. Gastrointestinal side effects are ...

Use of cutting-edge weight-loss drugs like Ozempic and Zepbound has increased dramatically among people with type 1 diabetes, raising safety concerns among experts, a new study says.

LINCOLN, Neb. (KOLN) - Popular GLP-1 drugs have been gaining traction across the United States as a means for weight loss. The drug has been approved to help treat type-2 diabetes, but a new study ...